Unlocking Hope for Cancer Patients Using PDT
ASX ANNOUNCEMENT
INVESTOR PRESENTATION FOR EAST-WEST SUMMIT
INVION
MELBOURNE (AUSTRALIA) 05 March 2024: Invion Limited (ASX: IVX) ("Invion" or the "Company")
wishes to release the attached presentation, which will be presented by the Company's
Executive Chair and Chief Executive Officer, Thian Chew, at the BioCentury-Bay Helix East-West
Summit in Singapore this afternoon.
This announcement was approved for release by Thian Chew, Chairman of the Board.
Investor and Media enquiries:
Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: [email protected]
Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: [email protected]
About Invion
Invion is a life-science company that is leading the global research and development of the
Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious
diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive
distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan
and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive
rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau,
the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently
acquired the rights to the United States, Canada and Hong Kong for infectious diseases.
Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group
Limited. Invion is listed on the ASX (ASX: IVX).
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as a novel next generation Photodynamic
Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and
promote an anti-cancer immune response. Less invasive than surgery and with minimal side
effects, PDT offers an alternative treatment option aimed at achieving complete tumour
regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity
across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the
potential to address the global challenge of antibiotic-resistant "superbugs".
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.comView entire presentation